JP2006502086A5 - - Google Patents

Download PDF

Info

Publication number
JP2006502086A5
JP2006502086A5 JP2003559480A JP2003559480A JP2006502086A5 JP 2006502086 A5 JP2006502086 A5 JP 2006502086A5 JP 2003559480 A JP2003559480 A JP 2003559480A JP 2003559480 A JP2003559480 A JP 2003559480A JP 2006502086 A5 JP2006502086 A5 JP 2006502086A5
Authority
JP
Japan
Prior art keywords
carbons
amino acid
branched
hydrogen
linear
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003559480A
Other languages
English (en)
Japanese (ja)
Other versions
JP4959919B2 (ja
JP2006502086A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/041299 external-priority patent/WO2003059317A2/en
Publication of JP2006502086A publication Critical patent/JP2006502086A/ja
Publication of JP2006502086A5 publication Critical patent/JP2006502086A5/ja
Application granted granted Critical
Publication of JP4959919B2 publication Critical patent/JP4959919B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003559480A 2001-12-21 2002-12-20 官能基を有するポリエチレングリコール賦形剤を用いた医薬用エアロゾル組成物 Expired - Fee Related JP4959919B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34278701P 2001-12-21 2001-12-21
US60/342,787 2001-12-21
PCT/US2002/041299 WO2003059317A2 (en) 2001-12-21 2002-12-20 Medicinal aerosol compositions with a functionalized polyethyleneglycol excipient

Publications (3)

Publication Number Publication Date
JP2006502086A JP2006502086A (ja) 2006-01-19
JP2006502086A5 true JP2006502086A5 (enExample) 2006-03-02
JP4959919B2 JP4959919B2 (ja) 2012-06-27

Family

ID=23343270

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003559480A Expired - Fee Related JP4959919B2 (ja) 2001-12-21 2002-12-20 官能基を有するポリエチレングリコール賦形剤を用いた医薬用エアロゾル組成物

Country Status (8)

Country Link
US (1) US7718162B2 (enExample)
EP (1) EP1458357B1 (enExample)
JP (1) JP4959919B2 (enExample)
AT (1) ATE424186T1 (enExample)
AU (1) AU2002367032B8 (enExample)
CA (1) CA2470520A1 (enExample)
DE (1) DE60231428D1 (enExample)
WO (1) WO2003059317A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1458357B1 (en) 2001-12-21 2009-03-04 3M Innovative Properties Company Medicinal aerosol compositions with a functionalized polyethyleneglycol excipient
EP1458354A1 (en) * 2001-12-21 2004-09-22 3M Innovative Properties Company Medicinal aerosol formulations comprising ion pair complexes
CA2470498A1 (en) * 2001-12-21 2003-07-24 3M Innovative Properties Company Medicinal aerosol compositions with an amide and/or ester containing excipient compound
GB0614621D0 (en) 2006-07-24 2006-08-30 3M Innovative Properties Co Metered dose dispensers
GB0620700D0 (en) 2006-10-19 2006-11-29 3M Innovative Properties Co Metered dose valves and dispensers
NZ599344A (en) 2009-09-25 2015-02-27 Reddy’S Lab Ltd Dr Formulations comprising triptan compounds
US11337962B2 (en) 2009-09-25 2022-05-24 Upsher-Smith Laboratories, Llc Formulations comprising triptan compounds
US20120272951A1 (en) 2009-12-16 2012-11-01 3M Innovative Properties Company Formulations and methods for controlling mdi particle size delivery
GB201118188D0 (en) 2011-10-21 2011-12-07 3M Innovative Properties Co Manufacture of medicinal aerosol canisters
GB201210580D0 (en) 2012-06-14 2012-08-01 3M Innovative Properties Co Metered dose dispensing valve
GB201221063D0 (en) 2012-11-23 2013-01-09 3M Innovative Properties Co Metered dose dispensing valve
EP3649175A1 (en) 2017-07-07 2020-05-13 Basf Se Alkoxylated esteramines and salts thereof
CN117042803A (zh) * 2021-12-02 2023-11-10 丽泽润有限公司 具有多功能应用的天然赋形剂及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1163028B (de) * 1960-03-09 1964-02-13 Hoechst Ag Verfahren zur Polymerisation von Vinylchlorid
ATE71520T1 (de) * 1986-03-10 1992-02-15 Burghart Kurt Pharmazeutische zubereitung sowie verfahren zur herstellung derselben.
JP2573275B2 (ja) * 1986-03-10 1997-01-22 ブルグハルト,クルト 薬学的製剤及びその製造法
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
JP2854974B2 (ja) * 1990-06-29 1999-02-10 フアイソンズ・ピーエルシー 加圧エアロゾル組成物
WO1994008599A1 (en) * 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Ion-pairing of drugs for improved efficacy and delivery
ES2129117T3 (es) 1992-12-09 1999-06-01 Boehringer Ingelheim Pharma Formulaciones en disolucion en forma de aerosol medicinales estabilizadas.
KR100321649B1 (ko) * 1993-03-17 2002-07-22 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 에스테르,아미드또는머캅토에스테르로부터유도된분산보조제를함유하는에어로졸제제
DE69405719T2 (de) * 1993-03-17 1998-01-15 Minnesota Mining & Mfg Aerosolzubereitung, enthaltend ein aus einem diol-disäure-derivat abgeleitetes dispergiermittel
US5492688A (en) * 1993-04-28 1996-02-20 The Center For Innovative Technology Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable suspending, solubilizing, wetting, emulsifying or lubricating agent
JPH09506097A (ja) * 1993-12-02 1997-06-17 アボツト・ラボラトリーズ 非cfc噴射剤と共に用いるエアロゾル薬物調剤
US5508023A (en) * 1994-04-11 1996-04-16 The Center For Innovative Technology Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
ZA9711732B (en) * 1996-12-31 1998-12-28 Quadrant Holdings Cambridge Methods and compositions for improvement bioavailability of bioactive agents for mucosal delivery
US6126919A (en) * 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US6218353B1 (en) * 1997-08-27 2001-04-17 Micell Technologies, Inc. Solid particulate propellant systems and aerosol containers employing the same
US6136294C1 (en) * 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation
BR9914799A (pt) * 1998-10-27 2001-07-10 Alcon Lab Inc Sistema conservante para composições farmacêuticas administráveis topicamente contendo um sabão de ácido graxo/aminoácido
US6258857B1 (en) * 1999-02-04 2001-07-10 Kyowa Industrial Co., Ltd. Internal liquid composition contained as internal liquid in a releasing container and releasing container product
GB0016876D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Novel formulation
JP2004509159A (ja) 2000-09-22 2004-03-25 グラクソ グループ リミテッド 新規なアルカン酸誘導体
KR20030097876A (ko) 2001-05-21 2003-12-31 넥타르 테라퓨틱스 화학적으로 개질된 인슐린의 폐 투여
GB0125127D0 (en) 2001-10-19 2001-12-12 Glaxo Group Ltd Compounds
CA2470498A1 (en) * 2001-12-21 2003-07-24 3M Innovative Properties Company Medicinal aerosol compositions with an amide and/or ester containing excipient compound
EP1458357B1 (en) 2001-12-21 2009-03-04 3M Innovative Properties Company Medicinal aerosol compositions with a functionalized polyethyleneglycol excipient

Similar Documents

Publication Publication Date Title
ES2549763T3 (es) Composición para inhibición del proteasoma
JP3731899B2 (ja) 酸化窒素放出生体高分子含有医薬組成物
US20060051315A1 (en) Polymers for delivering peptides and small molecules in vivo
CA3238758A1 (en) Novel ionizable lipids and lipid nanoparticles and methods of using the same
JP5537431B2 (ja) ウイルス融合のインヒビターのコレステロール誘導体
KR970042553A (ko) 캠프토테신 유도체
CA3026802A1 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide statistique
PT95581A (pt) Processo para a preparacao de compostos peptidicos antagonistas do receptor do fibrinogenio
JP2003506491A5 (enExample)
ES2659778T3 (es) Conjugado farmacéutico de polietilenglicol-oligopéptido de aminoácidos-irinotecán y composición farmacéutica del mismo
JP2020512276A5 (enExample)
ES2373561T3 (es) Uso de derivados de 1,4-bis(3-aminoalquil)piperazina en el tratamiento de enfermedades neurodegenerativas.
KR20120125610A (ko) 시클로스포린 유사체
Sohma et al. Development of water-soluble prodrugs of the HIV-1 protease inhibitor KNI-727: importance of the conversion time for higher gastrointestinal absorption of prodrugs based on spontaneous chemical cleavage
JP2005514440A5 (enExample)
JP4959919B2 (ja) 官能基を有するポリエチレングリコール賦形剤を用いた医薬用エアロゾル組成物
Robles et al. Solid-phase synthesis of a nucleopeptide from the linking site of adenovirus-2 nucleoprotein,-Ser (p 5′ CATCAT)-Gly-Asp-. Convergent versus stepwise strategy
EP2776471A1 (en) Stable peptide-based furin inhibitors
JP2004537596A (ja) オリゴグアニジン輸送因子の二方向合成
DK149091C (da) Analogifremgangsmaade til fremstilling af peptider indeholdende 2-7 aminosyrerester, desaminodipeptider eller amider deraf med ubiquitin-lignende aktivitet eller farmaceutisk acceptable syreadditionssalte deraf
CN101891800A (zh) 饱和脂肪链醇rgd五肽酯化合物及其合成方法和用途
AU2008339610B2 (en) Methods of peptide modification
JPH07501312A (ja) 保護されたアミノ酸構成単位、生産と使用
ES2361921T3 (es) Inhibidores duales antitrombóticos que comprenden un residuo de biotina.
ATE402949T1 (de) Dipeptidtransglutaminaseinhibitoren und verfahren zu deren anwendung